Healthy Volunteers Clinical Trial
Official title:
Sub-Study Evaluating the Quality of Different Methods of Obtaining Informed Consent"
| Verified date | September 14, 2011 |
| Source | National Institutes of Health Clinical Center (CC) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This is a sub-study of a drug development study conducted by Pfizer, Inc. It will evaluate
how well people who participate in research studies understand from the study consent form
what the purpose of the study is, the risks and benefits of participating, the procedures
they will undergo and their right to withdraw from the study before it ends. It will compare
the understanding and satisfaction of those who are given a standard consent form with those
who are given a simpler, concise consent form and examine how their understanding of the
information is affected by the length, complexity, format, and reading level of the document.
People 18 years of age and older who are participating in a Pfizer drug development study and
who are able to read and write English may be eligible for this sub-study.
Participants in Pfizer's drug development study who agree to participate in this sub-study
are randomized to receive either the standard consent form or the concise consent form. The
standard consent consists of a detailed, multiple page consent form. The concise form is
simpler, written at a lower reading comprehension level. Both forms contain all of the
required elements of informed consent according to federal regulations, and include
information needed to make a decision about participating in the study. Each form also
contains information regarding participation in this sub-study. The standard group signs the
standard consent form; the concise group is given the standard consent after reviewing the
concise form and is asked to review and sign it.
After reviewing the consent form for the main study, participants complete a 20-minute
questionnaire that includes questions that measure understanding of study information such as
its purpose, risks and benefits, compensation schemes, and other information. Additional
questions ask about how the participants made the decision to enroll in the study.
| Status | Completed |
| Enrollment | 250 |
| Est. completion date | September 14, 2011 |
| Est. primary completion date | |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
- INCLUSION CRITERIA: All willing adults at least 18 years old who come to the Pfizer CRU to consider volunteering for a phase 1 study for which there is a consent sub-study and who are able to read and answer questions in English are eligible to participate in the sub-study. Only adults (over 18 years old) who can provide their own consent will be included. Because the consent forms for Pfizer studies are written in English, the sub-study will only include individuals who can read and answer questions in English. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Pfizer New Haven Clinical Research Unit | New Haven | Connecticut |
| Lead Sponsor | Collaborator |
|---|---|
| National Institutes of Health Clinical Center (CC) |
United States,
Bergler JH, Pennington AC, Metcalfe M, Freis ED. Informed consent: how much does the patient understand? Clin Pharmacol Ther. 1980 Apr;27(4):435-40. — View Citation
Edwards SJ, Lilford RJ, Thornton J, Hewison J. Informed consent for clinical trials: in search of the "best" method. Soc Sci Med. 1998 Dec;47(11):1825-40. Review. — View Citation
Sugarman J, McCrory DC, Powell D, Krasny A, Adams B, Ball E, Cassell C. Empirical research on informed consent. An annotated bibliography. Hastings Cent Rep. 1999 Jan-Feb;29(1):S1-42. — View Citation
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |